Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Placebo: early-phase trial registry

4 of 6 indexed Placebo trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Placebo: 6 US clinical trials tracked, 4 recruiting.

Placebo is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 3 of these trials.

Enrollment posture brief

Registry condition placebo

OPEN 4 | RECR 67% | LATE 0 | EARLY 4 | RANK #2866 | SPON 3

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Placebo (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Placebo

Placebo lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Placebo on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Placebo is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Placebo research.

    University of Maryland, Baltimore accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Placebo enrolment sits around 182 participants.

    Median target enrolment is 182 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.

  4. Placebo research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Named interventions

Most-linked intervention names on Placebo records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Naloxone Drug
2 trials
Saline Other
2 trials
Placebo Drug
2 trials
Cognitive Effort Expectancy Cues Behavioral
1 trials
Vicarious Pain Expectancy Cues Behavioral
1 trials
Pain Expectancy Cues Behavioral
1 trials
sham Virtual Reality Behavioral
1 trials
Active Virtual Reality Behavioral
1 trials

US sites by state

Facility locations filed on Placebo trials. A trial with sites in several states counts in each.

Maryland 4 trials
New Hampshire 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Placebo page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Placebo condition card totals 6 registered trials; most-linked intervention Naloxone; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.